Camille Chakiba
A5048961826- Sarcoma Diagnosis and Treatment
- Ovarian cancer diagnosis and treatment
- Testicular diseases and treatments
- Frailty in Older Adults
- Advanced Breast Cancer Therapies
- Breast Cancer Treatment Studies
- BRCA gene mutations in cancer
- Cancer Genomics and Diagnostics
- Uterine Myomas and Treatments
- PARP inhibition in cancer therapy
- HER2/EGFR in Cancer Research
- Nutrition and Health in Aging
- Beetle Biology and Toxicology Studies
- PI3K/AKT/mTOR signaling in cancer
- Endometrial and Cervical Cancer Treatments
- Cancer survivorship and care
- Cancer Treatment and Pharmacology
- Chronic Lymphocytic Leukemia Research
- Breast Lesions and Carcinomas
- Colorectal Cancer Treatments and Studies
- CAR-T cell therapy research
- Lung Cancer Treatments and Mutations
- Salivary Gland Tumors Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Cardiac tumors and thrombi
Institut Bergonié
2016-2025
International Breast Cancer Study Group
2021
Université de Bordeaux
2013-2020
Inserm
2014-2020
Institut Claudius Regaud
2019
Institut Curie
2019
Institut de Cancérologie de l'Ouest
2019
Centre Léon Bérard
2019
Institut Gustave Roussy
2019
Centre Georges François Leclerc
2019
To determine factors associated with early functional decline during first-line chemotherapy in older patients.Patients age ≥ 70 years receiving for cancer were prospectively considered inclusion across 12 centers France. Functional was defined as a decrease of 0.5 points on the Activities Daily Living (ADL) scale between beginning and second cycle. Factors sought from pretreatment abbreviated comprehensive geriatric assessment, including ADL, Instrumental ADL (IADL), Mini-Nutritional...
<h3>Importance</h3> Endometrial cancer is often hormone-dependent and treated with aromatase inhibitors. The PI3K-AKT-mTOR pathway deregulation observed in endometrial drives hormonal resistance, thus supporting the rationale of combining mTOR inhibitor endocrine therapy. <h3>Objective</h3> To evaluate safety efficacy vistusertib combination anastrozole treatment women hormone receptor−positive recurrent or metastatic cancer. <h3>Design, Settings, Participants</h3> VICTORIA study was a...
PURPOSE Platinum-based doublets with concurrent and maintenance bevacizumab are standard therapy for ovarian cancer (OC) relapsing after a platinum-free interval (PFI) >6 months. Immunotherapy may be synergistic chemotherapy. PATIENTS AND METHODS ATALANTE/ENGOT-ov29 (ClinicalTrials.gov identifier: NCT02891824 ), placebo-controlled double-blinded randomized phase III trial, enrolled patients recurrent epithelial OC, one to two previous chemotherapy lines, PFI Eligible were randomly...
Abstract A close relationship has been demonstrated between genomic complexity and clinical outcome in uterine smooth muscle tumors. We studied the profiles by array‐CGH of 28 fumarate hydratase deficient leiomyomas 37 with bizarre nuclei (LMBN) from 64 patients. Follow‐up was available for 46 patients (from three to 249 months, mean 87.3 months). All were alive without evidence disease. For 51 interpretable tumors Genomic Index (GI) 16.4 (median: 9.8; 1 57.8), significantly lower than GI...
Mutations of CTNNB1 have been implicated in tumorigenesis many organs. However, tumors harboring a translocation are extremely rare and this has never reported uterine mesenchymal neoplasm. We report novel t(2;3)(p25;p22) involving the GREB1 (intron 8) (exon 3) tumor resembling ovarian sex cord (UTROSCT), which exhibited extrauterine metastasis. The detected by RNA-sequencing was validated RT-PCR, resulted nuclear expression β-catenin. Juxtapositioning with GREB1, is overexpressed response...
In the general geriatric population, programs linking evaluation with interventions are effective for improving functional status and survival of patients. Whether or not these improve health related quality life (HRQoL) overall (OS) in older patients cancer is yet clear. Indeed, randomized data on effect such HRQoL rare conflicting. We describe rationale design a phase III multicenter trial aimed at assessing efficacy intervention management elderly cancer. Approximately 1200 patients, 70...
BackgroundIn the phase III OlympiAD trial, olaparib significantly increased progression-free survival (PFS) compared with chemotherapy of physician's choice in patients germline BRCA-mutated (gBRCAm), human epidermal growth factor 2 (HER2)-negative metastatic breast cancer (mBC). The IIIb LUCY trial assessed clinical effectiveness similar patients, a setting reflecting practice.MethodsThis open-label, single-arm (300 mg, twice daily) enrolled BRCAm, HER2-negative mBC who had received taxane...
The interim analysis of the phase IIIb LUCY trial demonstrated clinical effectiveness olaparib in patients with germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (mBC), median progression-free survival (PFS) 8.11 months, which was similar to that arm III OlympiAD (7.03 months). This prespecified provides final overall (OS) and safety data.
Abstract A genomic index (GI) tool using array comparative hybridization (aCGH) on tumor cells has emerged as independent prognostic factor associated with the risk of metastatic relapse in synovial sarcoma (SS). The aim was to assess GI pediatric patients SS, determine its value a factor. All pediatric/adolescent/young adults’ (<25 years) localized SS prospectively included European EpSSG‐NRSTS05 protocol contributive aCGH were selected. Definition 2 / C , where is total number...